Use of flutter VRP1 in the management of patients with steroid-dependent asthma

Respiration. 1994;61(3):126-9. doi: 10.1159/000196323.


We have assessed a new positive expiratory pressure device, the Flutter VRP1, in 20 patients with moderately severe asthma. Patients were studied for an initial 1-week 'run-in' period, followed by 2 weeks of the flutter device in one of which the ball-bearing was removed from the bowl. Peak expiratory flow rates, salbutamol inhaler requirements and visual analogue scores were recorded daily. Ease of sputum expectoration showed a significant improvement after 6 days of the flutter device, but there were no differences in objective measurements of lung function nor in salbutamol use. The device may be a useful adjunct to asthma therapy.

MeSH terms

  • Adult
  • Aged
  • Asthma / physiopathology
  • Asthma / therapy*
  • Combined Modality Therapy
  • Humans
  • Middle Aged
  • Peak Expiratory Flow Rate
  • Positive-Pressure Respiration / instrumentation*
  • Prednisolone / administration & dosage


  • Prednisolone